CODEXIS, INC. - 8-K Filing
Codexis reported Q1 2026 revenue of $15.2 million, up from $7.5 million in Q1 2025, driven by $6.3 million in revenue from the Merck Technology Transfer agreement. The company reiterated full-year 2026 revenue guidance of $72–$76 million and reported a net loss of $8.7 million, or $0.10 per share, compared to $20.7 million, or $0.25 per share, in the prior-year period. Codexis ended Q1 with $65.1 million in cash, which it expects to fund operations through 2027. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CDXS